Department of Health written question – answered on 2nd August 2016.

Alert me about debates like this

Photo of Lord Hunt of Kings Heath Lord Hunt of Kings Heath Shadow Spokesperson (Health), Shadow Deputy Leader of the House of Lords

To ask Her Majesty’s Government what assessment they have made of how best to evaluate the impact of vaccination programmes to prevent rare diseases of high severity, and in particular the cost-effectiveness of the vaccination of children.

Photo of Lord Prior of Brampton Lord Prior of Brampton The Parliamentary Under-Secretary of State, Department of Health

The Government bases its evaluation of vaccination programmes on the advice of the Joint Committee on Vaccination and Immunisation (JCVI), other expert groups and evidence from a wide range of epidemiologists and other experts. Their considerations include the impact of rare diseases, immunisation, and impacts on children. The methodology used to assess cost-effectiveness of regular (i.e. non-emergency) immunisation programmes is based on published National Institute for Health and Care Excellence guidance Guide to the methods of technology appraisal 2013. A copy of the guidance is attached.

The Cost Effectiveness Methodology for Immunisation Programmes and Procurements (CEMIPP) working group has reviewed whether any changes to the methodology might be appropriate for immunisation and the Government is considering the advice.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.